Kevin Kunzmann

New US county data suggest more general and family physicians per capita is positively linked to increased rates of full COVID-19 vaccination.

Steffen Schmitz-Valckenberg, MD, explains the close association between disease progression and uncovered risk alleles.

Veeral S. Sheth, MD, MBA, discusses the potential value of complement inhibitors for the at-need patient population.

The renowned expert joins to discuss the clinical characteristics, societal burdens, and promising therapy research surrounding the hematologic disease.

The monoclonal antibody is designed to reduce the need for red blood cell transfusions to hemolysis among adults with the rare disease.

In commemoration of Wear Red Day, here's a breakdown of how US regions differ in cardiovascular disease burden among women.

New findings observing links between visual acuity, disease progression and risk loci could inform new clinical studies of the leading cause of irreversible vision loss.

Monthly IV pegcetacoplan was associated with 39% reduced risk of progression from incomplete to complete RPE and outer retinal atrophy.

The application for NVX-CoV2373 is supported by promising data from 2 multinational trials conducted prior to the spread of the Omicron variant.

New data show use exceeding the recommended daily dose for sleep aid has increased nearly 4-fold in the last 15 years.

A new assessment of payer incentives offered through physician organizations suggest the dominating emphasis of quantity over quality in pay.

The approved indication is a first-of-its-kind for a novel therapy—a bispecific antibody injection treatment for the leading causes of blindness.

YOSEMITE and RHINE data further supports the novel agent for diabetic macular edema. A study investigators explains the impact of the new findings.

Perspective from trial investigators and ophthalmologists on the novel drug, just prior to its potential FDA approval.

An analysis of Vaccine Adverse Event Reporting System (VAERS) data suggests three-fourths of all myocarditis cases observed in the first 8 months of COVID-19 vaccination occurred in persons 30 years and younger.

New findings from CDC data show three-fourths of all myocarditis cases observed in the first 8 months of COVID-19 vaccination occurred in persons 30 years and younger.

The selective inhibitor therapy is being investigated for the treatment of 2 forms of chronic cough—an indication that's been unmet in 60 years.

The Temple-based investigator and expert joins Lungcast to review recent clinical trials, recommendations and non-surgical techniques for patients who have advanced COPD.

Analysis of 2 national surveys suggest a more than two-fold greater likelihood of depressed Americans endorsing a false fact about COVID-19 vaccines than others.

New data suggest hospitalized patients experience little difference in all-cause outcomes dependent on the busyness of their attending hospitalist.

Julia Haas, PhD, discusses her team's recent findings that one-third of patients in COVID-19 vaccine trials reported side effects after receiving a placebo dose.

Despite attempts climbing since 2008, investigators have observed no significant change in suicidal adults seeking care.

New data show "nocebo responses" are frequent in COVID-19 vaccine studies—which may drive recipients' expectation of side effects.

The 6 recommendations across 2 expert-led guidelines address the role of colonoscopy, CT scans and elective surgery, among other subjects of care.

From a new heart failure indication to a first-of-its-kind rare disease treatment, here's the most interesting PDUFA dates for the first half of the year.

A new survey shows physicians are voting more frequently. A study author explains what that may mean for the civic involvement of doctors.

An expert explains how flu monitoring, sequencing, and preventive strategies may be improved due to the pandemic.

Despite heightened public worry over "florona" cases, a meta analysis from China suggests co-infection of the respiratory viruses is not associated with more severe outcomes.

A public health expert discusses how the future of COVID-19 may be managed similarly to flu—and why vaccination efforts are similarly burdened.